Physician profile
Sonalis Bunin
NPI 1306007372
$698.43
in general payments reported to CMS, 2019-2025
10 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.52 · 2022: $51.72 · 2023: $192 · 2024: $80.79 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eurofins Viracor, LLC | $214.54 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.86 | 2023-2025 | Livtencity |
| Glaxosmithkline, LLC. | $77.65 | 2022-2023 | Benlysta, Jesduvroq |
| Veloxis Pharmaceuticals, INC. | $55.70 | 2022-2025 | Envarsus |
| Alexion Pharmaceuticals, INC. | $51.83 | 2023 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $51.69 | 2021-2023 | Lokelma |
| Merck Sharp & Dohme LLC | $40.97 | 2025 | Prevymis |
| Bayer Healthcare Pharmaceuticals INC. | $35.49 | 2025 | |
| Daiichi Sankyo INC. | $32.09 | 2023 | Injectafer |
| Irhythm Technologies, INC. | $28.61 | 2024 | Zio Xt Patch, Zio Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonalis Bunin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.